Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma Market

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal centre and posts germinal centre B-cells. 


Diffuse Large B-Cell Lymphoma Epidemiological Segmentation 

The Epidemiological Segmentation of Diffuse Large B-Cell Lymphoma in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases Of Diffuse Large B-Cell Lymphoma
  • Gender-Specific Cases Of Diffuse Large B-Cell Lymphoma
  • Age-Specific Cases Of Diffuse Large B-Cell Lymphoma
  • Type-Specific Cases Of Diffuse Large B-Cell Lymphoma
  • Stage-Specific Cases Of Diffuse Large B-Cell Lymphoma 


Diffuse Large B-Cell Lymphoma Epidemiology 

  • The total incident cases of DLBCL in 7MM in 2017 were 67,743  
  • The incident population of DLBCL in the United States were 28,659 in 2017 
  • The age-group with the highest incidence of DLBCL among 7MM in 2017 was observed in the 65–74 years  
  • Males have higher incident cases of DLBCL as compared to females 


Diffuse Large B-Cell Lymphoma Market

The market Size of DLBCL in 7MM in 2017 was USD 2,655 million 


Diffuse Large B-Cell Lymphoma Market Drivers

  • Rising Incidence among Aging population
  • Increase in R&D
  • CAR-T therapies approvals


Diffuse Large B-Cell Lymphoma Market Barriers

  • Availability of defined diagnostic tools
  • Delay in Diagnosis
  • The high cost of treatment


Diffuse Large B-Cell Lymphoma Emerging Drugs

The emerging drugs of the Diffuse Large B-Cell Lymphoma market are 

  • Lisocabtagene maraleucel
  • Brentuximab Vedotin
  • Loncastuximab Tesirine
  • Tafasitamab
  • Treakisym
  • Enzastaurin (DB102)
  • Ublituximab + Umbralisib
  • Blinatumomab
  • Aliqopa (Copanlisib/BAY 80-6946)
  • Imbruvica (Ibrutinib)
  • Odronextamab (REGN1979)
  • Imfinzi (durvalumab): Parsaclisib (INCB050465)
  • TC 110
  • DPX-Survivac
  • Acalabrutinib
  • AUTO3
  • Obinutuzumab
  • CLR 131
  • Debio1562

And many others. 


Diffuse Large B-Cell Lymphoma Key Players

The key players in the Diffuse Large B-Cell Lymphoma market are

  • Bristol-Myers Squibb
  • Seattle Genetics
  • Takeda
  • ADC Therapeutics
  • Morphosys
  • Incyte
  • SymBio Pharmaceuticals
  • Denovo Biopharma
  • TG Therapeutics
  • Amgen
  • Bayer
  • Janssen/Pharmacyclics (AbbVie Company)
  • Regeneron Pharmaceuticals
  • Celgene/Bristol Myers Squibb
  • Incyte Corporation
  • TCR2 Therapeutics
  • IMV, inc. & Merck
  • AstraZeneca
  • Autolus Therapeutics
  • Hoffmann-La Roche
  • Cellectar Bioscience
  • Debiopharm International 

 And many others.